phase III failure
Tonix tanks after Phase III failure
September 7, 2016Research and Development PTSD, fibromylagia, phase III failure, tonix, tonix pharmaceuticals
New York-based Tonix Pharmaceuticals has suffered an almost 60% fall in their share price, after the announcement that its fibromyalgia …
Vectura asthma treatment fails at Phase III
August 30, 2016Manufacturing and Production, Research and Development asthma, inhaler, phase III, phase III failure, vectura
Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted …
LMTX fails Phase III trial, monotherapy benefits seen
July 28, 2016Research and Development Alzheimer's, LMTX, TauRX, phase III, phase III failure
TauRX Therapeutics has reported Phase III clinical trial results for its novel tau aggregation inhibitor LMTX. The results indicated that …
Lilly pulls plug on basal insulin Peglispro
December 8, 2015Manufacturing and Production R&D, basal insulin peglispro, diabetes, lilly, peglispro, phase III failure
Lilly has decided to pull out of filing its diabetes drug basal insulin peglispro, after failing to convince regulators and …
Genmab pulls plug on Phase III Arzerra trial
November 24, 2015Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure
Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …
Otsuka, GW announce Sativex fails in Phase III cancer pain trials
October 28, 2015Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure
Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …
Lilly shares fall as company abandons evacetrapib development
October 13, 2015Manufacturing and Production evacetrapib, high cholesterol, lilly, phase III, phase III failure
Eli Lilly shares fell by nearly 8% this week as the company announced it will abandon developmenty of the investigational …
Roche abandons Phase III cholesterol drug
May 8, 2012Medical Communications, Research and Development, Sales and Marketing CETP inhibitor, Roche, cardiovascular, dalcetrapib, phase III failure
Roche has abandoned its Phase III cholesterol treatment dalcetrapib after disappointing results.The manufacturer is ceasing work on the drug, once …
Latest content
Five Facts about cardiovascular disease
